Mechanism
Tesamorelin Research: GHRH Analog Published Findings
Updated · 8 cited sources · ResearchChem Research Team
Short answer: Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH). It works by stimulating the body's own synthesis and release of growth hormone (GH), not by supplying GH directly. Most of the published research comes from randomized, placebo-controlled trials in people with HIV and excess abdominal fat. In those trials it reduced visceral adipose tissue, raised IGF-I and improved some lipid measures, without clinically meaningful changes in glucose over the longer term. Later trials looked at liver fat and liver gene expression, with reported reductions in hepatic fat fraction. This review summarizes those findings for research purposes only.
What is tesamorelin?
Tesamorelin is a synthetic analog of human growth hormone-releasing hormone, also called growth hormone-releasing factor (GHRF) [6]. The phase 3 trial literature describes it as a GHRH(1-44) analog [2]. Review authors explain that GHRF analogues were developed because recombinant human GH, although effective for GH-deficient disorders, causes various adverse effects, and GHRF analogues may be better tolerated [8].
Tesamorelin was developed for conditions linked to a relative GH deficiency, with HIV-related lipodystrophy as the lead indication [8]. The FDA approved it in November 2010 for lipodystrophy associated with HIV infection [7]. One 2011 review described it as the first and only treatment indicated to reduce excess abdominal fat in HIV-associated lipodystrophy at that time [6].
How does tesamorelin act on the GH axis?
Tesamorelin works upstream of GH. It stimulates the synthesis and release of endogenous growth hormone instead of replacing the hormone itself [6]. Because the signal starts at the GHRH step, downstream markers such as insulin-like growth factor I (IGF-I) are the usual readout of its effect on the axis.
The trial data match this mechanism. In the first large randomized trial, IGF-I rose by 81.0% with tesamorelin and fell by 5.0% with placebo (P<0.001) [1]. In a pooled analysis of two phase 3 studies, IGF-I rose by 108 ± 112 ng/ml with tesamorelin and changed by −7 ± 64 ng/ml with placebo at week 26 [2]. A liver-biopsy analysis described the findings as clarifying the effects of pulsatile GH action, which separates this approach from giving GH directly [5].
What did the pivotal visceral fat trials find?
The first large randomized, placebo-controlled trial enrolled 412 patients with HIV and abdominal fat accumulation (86% men) and lasted 26 weeks [1]. The main outcome was the percent change in visceral adipose tissue (VAT), measured by computed tomography. Secondary outcomes included triglycerides, the ratio of total to HDL cholesterol, IGF-I and self-rated body image.
| Measure | Tesamorelin | Placebo |
|---|---|---|
| Visceral adipose tissue | −15.2% | +5.0% |
| Triglycerides | −50 mg/dl | +9 mg/dl |
| Total:HDL cholesterol ratio | −0.31 | +0.21 |
| IGF-I | +81.0% | −5.0% |
The authors reported no significant difference in overall adverse-event rates between groups, and no significant differences in glycemic measures. More patients in the tesamorelin group withdrew because of adverse events [1]. They concluded that 26 weeks of tesamorelin reduced visceral fat and improved lipid profiles [1].
Did the visceral fat effect last to 52 weeks?
A pooled analysis combined two multicenter phase 3 studies with 806 antiretroviral-treated patients, randomized 2:1 to tesamorelin or placebo for 26 weeks, followed by a 26-week safety extension [2]. At week 26 the treatment effect on VAT was −15.4%. Abdominal subcutaneous fat did not change significantly (treatment effect −0.6%). Triglycerides (−12.3%) and the cholesterol-to-HDL ratio (−7.2%) improved compared with placebo.
In the extension, patients who stayed on tesamorelin kept their VAT reduction at week 52 (−17.5 ± 23.3% versus the original baseline). Their reductions in waist circumference, triglycerides and non-HDL cholesterol were also maintained [2]. A separate review noted that VAT built up again after treatment was stopped [6]. Taken together, the pivotal data suggest the effect lasts only while treatment continues.
What has research shown about liver fat?
A smaller double-blind trial at Massachusetts General Hospital randomized 50 adults with HIV and abdominal fat accumulation to tesamorelin or placebo for 6 months, with VAT and liver fat as the main outcomes [3]. VAT fell more with tesamorelin (treatment effect −42 cm², P = .005). Liver fat, measured as the lipid-to-water percentage, also fell more, with a net effect of −2.9% (P = .003). The authors called this a preliminary study showing modest reductions in liver fat [3].
A later randomized, double-blind multicentre trial enrolled 61 people with HIV and non-alcoholic fatty liver disease (NAFLD), defined as a hepatic fat fraction (HFF) of 5% or more on proton magnetic resonance spectroscopy [4]. Over 12 months, HFF fell more with tesamorelin than with placebo: an absolute effect of −4.1% and a relative reduction of −37% from baseline. At 12 months, 35% of the tesamorelin group and 4% of the placebo group had HFF below 5% [4]. The authors said longer studies are needed to find out the effects on liver histology.
What do liver gene-expression studies add?
Researchers used paired liver biopsies from the NAFLD trial to find gene pathways that tesamorelin changed differently from placebo [5]. Gene set enrichment analysis showed higher expression of hallmark gene sets for oxidative phosphorylation. It showed lower expression of gene sets involved in inflammation, tissue repair and cell division.
Tesamorelin also moved gene sets linked to good and poor hepatocellular carcinoma prognosis in opposite directions. Among treated participants, these changes tracked with a better fibrosis-related gene score [5]. The same abstract states that, in the parent trial, tesamorelin prevented fibrosis progression over 1 year. The authors present the transcriptomic data as a possible mechanism for the clinical liver effects [5].
What do the trials report on glucose and safety?
Because GH can affect glucose handling, glycemic measures were tracked closely. The pooled phase 3 analysis found no clinically meaningful differences in glucose measures at weeks 26 and 52 and described tesamorelin as generally well tolerated [2]. In the 6-month liver trial, fasting glucose was higher with tesamorelin at 2 weeks (treatment effect 7 mg/dL, P = .03), but this difference was no longer significant across the study [3]. In the 12-month NAFLD trial, changes in fasting glucose and glycated haemoglobin did not differ between groups. The tesamorelin group had more injection-site complaints, none of them judged serious [4].
In a 2011 review, treatment-emergent serious adverse events occurred in fewer than 4% of patients over 26 weeks. Reported adverse events included injection-site reactions and effects associated with GH, such as arthralgia, headache and peripheral oedema [6]. Review authors also noted the lack of long-term safety and adherence data as a limitation [7].
Where are the gaps in the published evidence?
Nearly all of the controlled data come from one population: people with HIV who have central or ectopic fat accumulation. A 2009 review found that, apart from HIV-related lipodystrophy, other possible uses for tesamorelin looked less promising on the data available at the time [8]. A later review noted limited data supporting off-label uses [7]. Long-term histology results are still pending in the liver work [4]. Researchers reading this literature should treat findings outside these study populations as untested. This material is provided for research reference only and is not guidance on human use.
Frequently asked questions
Is tesamorelin a GHRH analog or a ghrelin-receptor agonist?
Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH). It stimulates the synthesis and release of endogenous GH. It is not a ghrelin-receptor agonist.
What was the main outcome in the tesamorelin phase 3 trials?
The main outcome was the percent change in visceral adipose tissue measured by CT. In the pooled analysis of two phase 3 trials, the treatment effect at week 26 was −15.4% compared with placebo.
Does tesamorelin reduce subcutaneous fat?
In the pooled phase 3 data, abdominal subcutaneous fat did not change significantly. The authors described subcutaneous fat as preserved while visceral fat fell.
What did the NAFLD trial in HIV find?
Over 12 months, hepatic fat fraction fell more with tesamorelin than placebo (absolute effect −4.1%, relative −37%). At 12 months, 35% of the tesamorelin group and 4% of the placebo group had a fat fraction below 5%.
Did tesamorelin raise blood glucose in trials?
The pooled phase 3 analysis and the 12-month NAFLD trial found no clinically meaningful between-group differences in glucose measures. One 6-month study saw a short-term rise in fasting glucose at 2 weeks that was not significant across the study.
Cited studies
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV.. N Engl J Med. 357(23):2359-70 (2007). PubMed 18057338 DOI
- Falutz J, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.. J Clin Endocrinol Metab. 95(9):4291-304 (2010). PubMed 20554713 DOI
- Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.. JAMA. 312(4):380-9 (2014). PubMed 25038357 DOI
- Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.. Lancet HIV. 6(12):e821-e830 (2019). PubMed 31611038 DOI
- Fourman LT, Billingsley JM, Agyapong G, et al. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.. JCI Insight. 5(16):e140134 (2020). PubMed 32701508 DOI
- Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy.. Drugs. 71(8):1071-91 (2011). PubMed 21668043 DOI
- Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy.. Ann Pharmacother. 46(2):240-7 (2012). PubMed 22298602 DOI
- Wang Y, Tomlinson B. Tesamorelin, a human growth hormone releasing factor analogue.. Expert Opin Investig Drugs. 18(3):303-10 (2009). PubMed 19243281 DOI
Research use only. ResearchChem products are laboratory reagents for in-vitro research. They are not for human or veterinary consumption and are not intended to diagnose, treat, cure or prevent any disease. This article summarizes published research for educational purposes and is not medical advice.